iSOFT Completes Agreements for New Life Science Research Tool

iSOFT Group LimitediSOFT Group Limited (ASX:ISF), one of the world's largest healthcare IT companies, has moved into the life science space with solutions that extract and de-identify clinical data from electronic medical records for clinical research and other secondary uses.

The move follows a co-marketing agreement with US-based CliniWorks for its AccelFind solutions. CliniWorks has developed the technology behind AccelFind, and provides it as a service, to extract medical knowledge from any type of data, including free text notes, discharge summaries or the structured data contained in electronic medical records and laboratory systems. With the new agreement, iSOFT will market AccelFind as part of its Life Science Solution "powered by CliniWorks" to hospitals and life science companies worldwide.

Meanwhile Cytolon, a Berlin-based enabling technology company for personalized medicine, will integrate the new tool with its platform CordMatch. CordMatch is a unique, web-based platform that integrates product search and matching-to-patient, logistics, billing and follow-up for the matching of stem cell products. The Life Sciences Solution, will also be integrated with CordMatch and provide a powerful tool allowing the secondary use of electronic health records, so offering a whole new world of possibilities for clinical development, adding value for pharmaceutical companies and permitting ultimately the improvement of therapy quality and fostering personalized medicine. Benefits generated from these projects will be shared between the companies.

Cytolon supports and participates in clinical research studies for the development of future applications of stem cell products derived from umbilical cord blood for a variety of diseases.

The iSOFT Life Sciences solution integrates with all standard hospital databases to extract clinical information and so promotes knowledge collaboration for highly efficient clinical research, outcomes tracking and management.

iSOFT's Director for Life Sciences, Dr Joerg Kraenzlein, said: "This is a tremendous opportunity to accelerate clinical research in a so far unprecedented way, and tap into new areas of treatment options and value propositions that have the potential to change the way we perform medicine and use healthcare IT today."

iSOFT's Chief Medical Officer, Dr Michael Dahlweid, added: "Life Sciences is a new strategic asset of iSOFT's solution portfolio with a huge growth potential and perfectly fits our Smart Solution approach, which provides instant value to existing and new customers."

Related news articles:

About iSOFT Group
iSOFT Group Limited (ASX: ISF) is the largest health information technology company listed on the Australian Securities Exchange, and among the world's biggest providers of advanced application solutions in modern healthcare economies.

iSOFT works with healthcare professionals to design and build software applications that answer all of the difficult questions posed by today’s healthcare delivery challenges. Our solutions act as a catalyst for change, supporting free exchange of critical information across diverse care settings and participating organizations.

Today, more than 13,000 provider organizations in over 40 countries use iSOFT's solutions to manage patient information and drive improvements in their core processes. The group's sustainable development is delivered through careful planning, in-depth analysis of the market, and anticipation of our clients' evolving requirements. Our business is driven by the collective talent, experience and commitment of more than 3,500 specialists in 19 countries worldwide.

A global network of iSOFT subsidiaries, supported by an extensive partner network, provides substantial experience of national healthcare markets. As a result, we offer our clients comprehensive knowledge of local market requirements in terms of culture, language, working practices, regulation and organizational structure.

www.isofthealth.com

Most Popular Now

AI Catches One-Third of Interval Breast …

An AI algorithm for breast cancer screening has potential to enhance the performance of digital breast tomosynthesis (DBT), reducing interval cancers by up to one-third, according to a study published...

Great plan: Now We need to Get Real abou…

The government's big plan for the 10 Year Health Plan for the NHS laid out a big role for delivery. However, the Highland Marketing advisory board felt the missing implementation...

Researchers Create 'Virtual Scienti…

There may be a new artificial intelligence-driven tool to turbocharge scientific discovery: virtual labs. Modeled after a well-established Stanford School of Medicine research group, the virtual lab is complete with an...

From WebMD to AI Chatbots: How Innovatio…

A new research article published in the Journal of Participatory Medicine unveils how successive waves of digital technology innovation have empowered patients, fostering a more collaborative and responsive health care...

New AI Tool Accelerates mRNA-Based Treat…

A new artificial intelligence (AI) model can improve the process of drug and vaccine discovery by predicting how efficiently specific mRNA sequences will produce proteins, both generally and in various...

AI also Assesses Dutch Mammograms Better…

AI is detecting tumors more often and earlier in the Dutch breast cancer screening program. Those tumors can then be treated at an earlier stage. This has been demonstrated by...

RSNA AI Challenge Models can Independent…

Algorithms submitted for an AI Challenge hosted by the Radiological Society of North America (RSNA) have shown excellent performance for detecting breast cancers on mammography images, increasing screening sensitivity while...

AI could Help Emergency Rooms Predict Ad…

Artificial intelligence (AI) can help emergency department (ED) teams better anticipate which patients will need hospital admission, hours earlier than is currently possible, according to a multi-hospital study by the...

Head-to-Head Against AI, Pharmacy Studen…

Students pursuing a Doctor of Pharmacy degree routinely take - and pass - rigorous exams to prove competency in several areas. Can ChatGPT accurately answer the same questions? A new...

NHS Active 10 Walking Tracker Users are …

Users of the NHS Active 10 app, designed to encourage people to become more active, immediately increased their amount of brisk and non-brisk walking upon using the app, according to...

New AI Tool Illuminates "Dark Side…

Proteins sustain life as we know it, serving many important structural and functional roles throughout the body. But these large molecules have cast a long shadow over a smaller subclass...

Deep Learning-Based Model Enables Fast a…

Stroke is the second leading cause of death globally. Ischemic stroke, strongly linked to atherosclerotic plaques, requires accurate plaque and vessel wall segmentation and quantification for definitive diagnosis. However, conventional...